Introduction to INOmax EVOLVE DS Delivery System
Mallinckrodt plc, a prominent global specialty pharmaceutical company, is thrilled to announce the expanded rollout of its next-generation nitric oxide delivery system, the INOmax EVOLVE DS. This innovative device has been designed with advanced features to better support neonatal intensive care unit (NICU) patients and healthcare professionals.
Features of the INOmax EVOLVE DS
The INOmax EVOLVE DS is a breakthrough in inhaled nitric oxide delivery systems, providing a fully integrated design that combines automation and user-friendly features. The system consists of a primary delivery system, an electronic medical record (EMR) connectivity option, and mini-cylinder technology. All of these components work together to streamline the user experience while enhancing safety during treatment.
Launch and Availability
This modern system is now available for contracting and distribution in U.S. hospitals. Mallinckrodt's previous successful pilot program has paved the way for this nationwide rollout, highlighting the device’s capability to meet the critical needs of NICU patients.
Benefits for Healthcare Professionals
The INOmax EVOLVE DS is specifically designed to enhance safety and reduce the burden on healthcare staff. It features an automated pre-use checkout process, electronic blending, and a touchscreen display that supports ease of operation. The device ensures that healthcare professionals can focus more on patient care while efficiently managing treatment protocols.
Patient and Device Safety
The INOmax delivery system is essential for treating term and near-term neonates suffering from hypoxic respiratory failure related to pulmonary hypertension. It's vital for healthcare providers to adhere to indicated usage and warnings while using the device.
Positive Feedback from Pilot Program
Feedback from healthcare professionals who participated in the pilot program has been overwhelmingly positive. One Respiratory Therapist noted the improved mobility and design of the device, stating it significantly eases the movement of equipment while providing effective treatment solutions.
Commitment to Quality and Continuous Improvement
Mallinckrodt is dedicated to extensive research and development, resulting in over 20 years of established efficacy and safety profiles for INOmax. With more than 875,000 patients treated globally, the company continues to innovate to enhance treatment outcomes.
Acknowledgment of Recognition
In recognition of its innovative design, the INOmax EVOLVE DS was recently awarded the Human Factors and Ergonomics Society’s Stanley Caplan User-Centered Product Design Award. This acknowledgment underscores Mallinckrodt's commitment to innovation in medical devices.
Future Prospects and Contact Information
As Mallinckrodt continues to support the medical community, they invite healthcare professionals to reach out for information about the INOmax EVOLVE DS or attend product demonstrations. For any inquiries regarding the delivery system, interested parties can call (877) 566-9466 or contact their local representative.
Frequently Asked Questions
What is the purpose of the INOmax EVOLVE DS delivery system?
The INOmax EVOLVE DS is designed for the delivery of nitric oxide to treat neonatal hypoxic respiratory failure associated with pulmonary hypertension.
How does the automated system benefit healthcare providers?
It reduces manual tasks, enhances safety features, and streamlines patient care, allowing healthcare providers to focus more on achieving optimal patient outcomes.
Who can use the INOmax EVOLVE DS?
The delivery system is intended for use by medical professionals in NICUs for term and near-term neonates diagnosed with specified conditions.
What recognition has the INOmax EVOLVE DS received?
It was awarded the Stanley Caplan User-Centered Product Design Award for its innovative approach to design and usability.
How can someone learn more about the INOmax EVOLVE DS?
Interested individuals can reach out to their local representative or visit Mallinckrodt’s dedicated websites for further information and updates.
